Nova Patents
ATE504292T1

Oral formulation of anhydrous olanzapine form i

Abstract

This record has no abstract on file.

Term

0.2 yearsto projected expiry

Projected expiry 19 December 2026, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

17 members in 12 offices

This recordMember, by publication datePriority claim2 more offices are in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
200503183SpainA
75410405United States of AmericaP
2006069905European Patent Office (EPO)W

Members17

Family members, oldest first
DocumentOfficeKind
WO2007074110A1World Intellectual Property Organization (WIPO)A1
ES2279715A1SpainA1
ES2279715B1SpainB1
KR20080080230ARepublic of KoreaA
EP1965773A1European Patent Office (EPO)A1
US2008311203A1United States of AmericaA1
JP2009521518AJapanA
EP1965773B1European Patent Office (EPO)B1
AT504292TAustriaT
ATE504292T1This recordAustriaT1
DE602006021231D1GermanyD1
ES2359647T3SpainT3
PT1965773EPortugalE
DK1965773T3DenmarkT3
SI1965773T1SloveniaT1
PL1965773T3PolandT3
US8962018B2United States of AmericaB2